YNHHS Initial Treatment Algorithm for Hospitalized ADULTS with Non Severe* COVID-19

Disclaimer: There are no FDA-approved treatments for COVID-19, supportive care is standard of care.
Limited treatment data are available & clinical judgment is warranted Algorithm last updated 4/3/20

Patient with confirmed POSITIVE SARS-CoV-2 by PCR

*(If mechanically ventilated or on ECMO, proceed to Severe algorithm)

A-Presence of : B-Presence of:

Ox gen saturation on room air OR on 1) Fever and/or signs & symptoms of
chronic O2 supplementation (if O2>93% see box B) respiratory disease (e.g. cough, dyspnea)
OR
YES NO 2) Chest X-Ray showing lung opacities
YES
SUPPORTIVE CARE &
EVERY 4 HOUR Does patient have:
START TREATMENT OXYGEN MONITORING
NO Age > 60 OR
(see treatment below) BMI > 30 OR
Evaluate for Clinical Trials Diabetes (HgbA1c > 8.0) OR
(YNHH only)
Chronic heart disease/HTN OR
Chronic lung disease OR
Immunosuppressed*
If Ox gen saturation on room air
YES
START TREATMENT
TREATMENT
COVID-SPECIFIC TESTS
Start hydroxychloroquine x 5 days 1) Baseline & every 12 hours: CRP, Troponin, D-
Assess Clinical Trial Eligibility (YNHH only) dimer
2) Baseline & every 24 hours: CBC with differential,
If Liter O requirement
CMP, Ferritin, Procalcitonin, BNP, fibrinogen, PT/PTT,
OR Liter O requirement hs-CRP >70 Mg
Consider tocilizumab
3) Baseline & every 48 hours: Cytokine panel,
Consider MICU evaluation if > 4 Liter O2 requirement or Angiotensin II level
hemodynamic instability
(at YNHH see attached appendix 2 for suggested triage guidelines) 4) Baseline EKG, and if not on telemetry, daily EKG.
(see appendix 1 for additional recommendations)
YNHH: ID consult is not mandatory; consider ID input if 5) Repeat Chest X-Ray: if clinical deterioration. (CXR
immunosuppressed* or clinically decompensating not indicated for discharge or to document clinical
BH, GH, LMH, or WH: consult ID improvement)
*Immunosuppression includes following: Cancer treatment Cardiac: If significantly elevated troponin or EKG
within 1 year, the use of immunosuppressive drugs abnormalities and/or concern for CHF, consider TTE and
biologic ch onic edni one mg dail olid o gan cardiology input
transplant, bone marrow transplantation, HIV/AIDS
Hematologic: All patients should receive prophylactic
(regardless of CD4 count), leukemia, lymphoma, SLE, and enoxaparin unless contraindicated (see appendix 3 for
vasculitis. dosing recommendations)

Algorithm reviewed by YNHHS SAS and YNHH/YSM Ad-Hoc COVID-19 Treatment Team
YNHHS Initial Treatment Algorithm for Hospitalized ADULTS with Severe COVID-19
Disclaimer: There are no FDA-approved treatments for COVID-19, supportive care is standard of care.
Limited treatment data are available & clinical judgment is warranted - Algorithm last updated 4/3/20

Respiratory failure, including Mechanical ventilation and ECMO PLUS

confirmed POSITIVE SARS-CoV- b PCR

TREATMENT
YNHH: consider ID input as needed
Start Hydroxychloroquine x 5 days BH, GH, LMH, or WH: consult ID
Assess Clinical Trial Eligibility (YNHH only)

Cardiac:
Consider tocilizumab x 1 dose -Monitor electrolytes: Replete Mg >2, K >4
(in combination with hydroxychloroquine) -Baseline EKG daily, monitor telemetry closely
for QTc Prolongation
-Caution combining QTc prolonging medications
-If significantly elevated troponin or EKG
If progression in 48 hours despite tocilizumab abnormalities and/or hemodynamic instability,
(worsening respiratory/clinical status or consider POCUS for LV function assessment and
worsening inflammatory markers): cardiology consult
(Appendix 1 for additional recommendations)
Consider methylprednisolone 40mg Q8H for
72 hours. Reassess for extended course or
taper (up to 5-7 days total). Hematologic:
-If D-dimer < 10 mg/L: All patients should receive
Steroids given at discretion of primary team
standard prophylactic enoxaparin unless
contraindicated★
COVID-SPECIFIC TESTS -If D-dimer mg/L: use weight-based
1) Baseline & every 12 hours: CRP, Troponin, D- enoxaparin prophylaxis unless contraindicated★
dimer -If sudden and unexplained change in O2
2) Baseline & every 24 hours: CBC with differential, OR new asymmetrical upper or lower extremity
CMP, Ferritin, Procalcitonin, BNP, fibrinogen, PT/PTT, edema, consider venous U/S of affected extremity
Mg -If confirmed VTE, start therapeutic dose
3) Baseline & every 48 hours: Cytokine panel, anticoagulation unless contraindicated★.
Angiotensin II level -If signs of nasal or digital ischemia OR ferritin
4) Baseline EKG, and if not on telemetry, daily EKG. >100,000, consider Hematology consult at
(see appendix 1 for additional recommendations) discretion of primary team
5) Repeat Chest X-Ray: if clinical deterioration. (★see appendix 3 for dosing recommendations)

Algorithm reviewed by YNHHS SAS and YNHH/YSM Ad-Hoc COVID-19 Treatment Team
 Currently recommended medications for COVID
(Subject to change as more data becomes available and based on medication availability)
Notable Adverse
Drug Dose Mechanism Rationale for use Other considerations
Reactions
Prevents
400mg PO In-vitro data shows
acidification of There is a theoretical potential for an increase in
q12h x 24h potent SARS-COV-2
endosomes hydroxychloroquine levels when used with atazanavir
followed by inhibition and early QTc prolongation
interrupting therefore monitor for possible QTc prolongation
Hydroxy- 200mg clinical data shows Rash
cellular functions
chloroquine q12h x 4 possible benefit Retinopathy is rare
and replication For patients with NG/OG/NT hydroxychloroquine can be
(HCQ)1-9 days for a 5 (Baseline eye exam
Prevents viral entry crushed for enteral administration
day total HCQ was found more is not required for
via ACE2 binding
duration potent than chloroquine use for COVID-19)
Reduction of viral The ap can be e ended pa da ba ed on pa ien
then re- in inhibiting SARS-CoV-2
infectivity clinical response, but should not exceed 10 total days
assess in vitro
Immunomodulator
IMMUNOMODULATING AGENTS
8mg/kg IV IL-6 receptor antagonist
x 1 dose may attenuate cytokine Headache
release in patients with The use of IL-6 levels should NOT guide decision to
(actual Monoclonal Elevated liver
Tocilizumab10-13 severe disease administer tocilizumab at this time
body antibody to IL6 enzymes
weight); receptor Retrospective data Infusion reactions
Additional doses not indicated at this time
dose max suggest possible benefit (e.g. flushing, chills)
800 mg) (clinical trials ongoing)
Medications which may be available through Clinical Trials
(Subject to change as more data becomes available and based on medication availability)
As of 3/22/20 remdesivir is available through clinical trials
In-vitro data reveals only and not through compassionate use except for
Viral RNA Nausea, vomiting,
Clinical potent SARS-COV-2 pregnant patients and those < 18 years of age still have
dependent RNA Elevated liver
Remdesevir14-16 Trial inhibition and early the option for compassionate use program
polymerase enzymes
dosing clinical data shows
inhibitor Rectal bleeding
possible benefit Gilead is working on an expanded access program
IMMUNOMODULATING AGENTS
Elevated liver
IL-6 receptor antagonist
Clinical Monoclonal enzymes
may attenuate cytokine
Sarulimab17-19 Trial antibody to IL6 Leukopenia Available through clinical trial only at this time
release in patients with
dosing receptor Infusion reactions
severe disease
(e.g. flushing, chills)
Medications NOT currently recommended as first line for COVID
(Can be considered in certain cases after discussion with Infectious Diseases and Pharmacy)
Drug Dose Mechanism Rationale for possible efficacy Rationale for NOT including as first line agent
400mg/100
Lopinavir/ mg PO Limited availability, poor tolerability (such as GI side
Viral protease
Ritonavir8,20 q24h x 5 In-vitro data reveals potent SARS-COV-2 inhibition effects) and recent data demonstrated questionable
inhibitor
days then clinical efficacy
reassess
Mild indirect hyperbilirubinemia is common and not
indicative of hepatic dysfunction
CYP enzyme inhibitor (3A4, 2C8) monitor/discuss with
pharmacy potential for drug-drug interactions
For patients with NG/OG/NJ open capsules for enteral
Atazanavir21
administration
400mg
More potent binding to the virus compared to other Atazanavir needs an acidic environment for absorption
NO LONGER (2-200mg
protease inhibitors in vitro (lower than lopinavir) and therefore antacids, H2 blockers, proton pump
RECOMMENDED caps) PO Viral protease
inhibitors (PPIs) should be avoided. If these agents must
AS FIRST LINE q24h x 5 inhibitor
Drug more widely available than o he PI incl ding be given the administration should be separated as below:
due to updated days then
lopinavir/ritonavir and better tolerated o Atazanavir should be given 2 hours before or
Lopinavir re-assess
1 hour after antacids
/ritonavir data19
o Atazanavir should be given at the same time
as the H2 blocker or the atazanavir should be
given 10 hours after or 2 hours before the H2
blocker
For PPIs avoid concomitant use
 Very limited data on use of azithromycin alone or in
combination with other agents
500 mg x 1,
o Gautret, et al. study is limited by small sample size
followed by Not well defined; In a small study, combination of HCQ and azithromycin
Azithromycin22 (only 6 patients received HCQ & azithromycin
250 mg possible was associated with significant a reduction in SARS-
combination) and those patients had lower viral loads
q24h x 4 immunomodulator CoV-2 viral load
than other included patients
days
Combination of HCQ and azithromycin and atazanavir can
increase the risk for QTc prolongation
800 mg
Darunavir/ /150 mg Viral protease Decreased binding to viral protease compared to
In-vitro data shows SARS-COV-2 inhibition
Cobicistat23 PO q24h inhibitor atazanavir. No clinical data at this time
x 5 days
Viral RNA
Limited evidence for SARS-CoV-2 and toxicity risk
polymerase
outweighs benefit of use
inhibitor and In vitro data for use in SARS-CoV and MERS-CoV
Ribavirin24-26 N/A Typically used with interferon
inhibition of indicates possible activity
Studied in patients with other coronaviruses with mixed
elongation of RNA
results
fragments
Inhibits influenza
No current data to support use of this drug.
virus
Additionally, SARS-CoV-2 does not use neuraminidase in
Oseltamivir27 N/A neuraminidase Activity against influenza virus
the replication cycle so mechanistically there would be no
blocking viral
benefit
release
Augments host
Nitazoxanide28 N/A In-vitro data reveals SARS-COV-2 inhibition No clinical data available
antiviral response
IMM M D LA I G AGE
Limited data with SARS-CoV-2, toxicity risk outweighs
Possible activity against SARS-CoV and MERS-CoV benefit of use
Interferon-
N/A Immunomodulator Have been studied for patients with other coronaviruses
beta29-31
Typically used in combination with ribavirin with mixed results
Not interferon-alpha or interferon-gamma
If
indicated Lack of effectiveness and potential harm shown in
per literature specifically inhibition of viral clearance in
protocol: Inhibit production severe influenza and SARS 31-34, though possible benefit
of inflammatory with critically ill COVID19 patients 35
Methyl- cytokines that
Corticosteroids prednisol regulate neutrophil May be helpful in attenuating cytokine release in May be considered for use by critical care team for
32-36
one and T-cell patients with severe disease salvage therapy
responses leading
40mg to immune Corticosteroids should be used if clinically indicated as
q8hr IV suppression part of standard of care such as for an asthma or COPD
for three exacerbation, or shock with history of chronic steroid
days, then use
re-assess
May have both antiviral and immunomodulatory
effects
Intravenous Neutralizing Drug is on critical national shortage and has an unclear
immunoglobulin N/A antibodies against role as current preparations will not contain antibodies
A recent observational study reported clinical and
(IVIG)37-38 the virus against SARS-CoV-2 at this time
radiographic improvement in 3 patients who
received high dose IVIG at time of respiratory distress
Janus Kinase (JAK)
Not available for off label use
inhibitor binding
May have targeted antiviral and immunomodulatory
cyclin G -
Baricitinib 39-40 N/A effect with less side-effects at an effective dose than No clinical data available
associated kinase,
other JAK inhibitors
may inhibit viral
Risk of severe infections with use
entry via
endocytosis
References:
1) Vincent MJ, Bergeron E, Benjannet S et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005; 2:69. (PubMed 16115318) (DOI 10.1186/1743-422X-2-69).
2) Olofsson S, et al. Avian influenza and sialic acid receptors: more than meets the eye? Lancet Infect Dis. 2005 Mar;5(3):184-8.
3) Yang ZY et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN.J Virol. 2004
Jun;78(11):5642-50.
4) Savarino A, et al. Anti-HIV Effects of Chloroquine: Inhibition of Viral Particle Glycosylation and Synergism With Protease Inhibitors. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):223-32.
5) Klumperman J, et al. Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding. J Virol. 1994 Oct;68(10):6523-34.
6) Schrezenmeier E and Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. doi: 10.1038/s41584-020-0372-x.
Epub 2020 Feb 7.
7) Zhonghua J, et al. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. CMAPH. 2020 Feb;43(0):E019. DOI: 10.3760/cma.j.issn.1001-0939.2020.0019.
8) Yao X, Ye F, Zhang M et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syn-drome Coronavirus 2 (SARS-CoV-2).
Clin Infect Dis. 2020; In Press. (PubMed 32150618) (DOI 10.1093/cid/ciaa237)
9) Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, Zhuang R, Hu B, and Zhang Z. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial.
Doi.org/10.1101/2020.03.22.20040758
10) Brudno JN & Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019 Mar;34:45-55. doi: 10.1016/j.blre.2018.11.002. Epub 2018 Nov 14.
11) Rubin DB, et al. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain. 2019 May 1;142(5):1334-1348. doi: 10.1093/brain/awz053.
12) Anecdotal reports from Italy; Chinese National Health Commission Clinical Guideline, March 3, 2020. http://busan.china-consulate.org/chn/zt/4/P020200310548447287942.pdf
13) Xiaoling Xu, et al. Effective treatment of Severe COVID-19 Patients with Tocilizumab. http://chinaxiv.org/abs/202003.00026. ( pre-print not peer reviewed)
14) Holshue ML, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-936.
15) Wang M, Cao R, Zhang L et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30:269-271. (PubMed 32020029) (DOI
10.1038/s41422-020-0282-0)
16) Clinical trials.gov (Identifier NCT04292899 and NCT04292730).
17) Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with
cytokine-directed therapy. Blood 2013; 121(26):5154-7.
18) Tomonori Ishii ea. 2019. Pharmacodynamic effect and safety of single-dose sarilumab SC or tocilizumab IV or SC in patients with rheumatoid arthritis. Annual Meeting of the American College of Clinical
Pharmacology. Bethesda, MD, USA.
19) Clinical Study Protocol 6R88-COV-2040 Original Regeneron Pharmaceuticals, Inc. Page 78
20) Cao B, Wang Y, Wen D et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; (PubMed 32187464) (DOI 10.1056/NEJMoa2001282)
21) Yu-Chuan et al, Potential therapeutic agents for COVID-19 based on the analysis of protease and RNA polymerase docking, doi:10.20944/preprints202002.0242.v1 (not peer reviewed).
22) Gautret P, Lagier JC, Parola P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimi-crob Agnts. 2020; In Press. (DOI
10.1016/jantimicag.2020.105949)
23) Clinicaltrials.gov (Identifier NCT04252274)
24) Gross AE, et al. Oral Ribavirin for the Treatment of Noninfluenza Respiratory Viral Infections: A Systematic Review. Ann Pharmacother. 2015 Oct;49(10):1125-35.
25) Arabi YM, Alothman A, Balkhy HH et al. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon- b MIRACLE ial d p o ocol fo a andomi ed
controlled trial. Trials. 2018; 19:81. (PubMed 29382391) (DOI 10.1186/s13063-017-2427-0)
26) Mo Y, Fisher D. A review of treatment modalities for Middle East Respiratory Syndrome. J Antimicrob Chemother. 2016 Dec;71(12):3340-3350.
27) Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507 513. PMID: 32007143
DOI: 10.1016/S0140-6736(20)30211-7.
28) Gamino- Arroyo AE, et al. Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness. Clin Infect Dis. 2019 Nov 13;69(11):1903-1911.
29) Cinatl J et al. Treatment of SARS with Human Interferons. Lancet. 2003; 362(9380): 293-294.
30) Chan JF-W, Yao Y, Yeung M-L, et al. Treatment With Lopinavir/Ritonavir or Interferon- b Imp o e O come of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. The Journal of
infectious diseases. 2015;212(12):1904-1913.
31) Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature communications. 2020;11(1):222.
32) Lee N, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004 Dec;31(4):304-9.
33) Stockman LJ, et al. SARS: systematic review of treatment effects. PLoS Med. 2006 Sep;3(9):e343.
34) Arabi et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome.Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767. doi: 10.1164/rccm.201706-1172OC.
35) WHO. COVID-19 Guidelines, 2020 .https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance
36) Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020 Mar 13.
doi: 10.1001/jamainternmed.2020.0994. PMID: 32167524.
37) Hu H, et al. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020 Mar 16. pii: ehaa190. doi: 10.1093/eurheartj/ehaa190.
38) Cao et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. Open Forum Infectious Diseases,
ofaa102, https://doi.org/10.1093/ofid/ofaa102
39) Richardson P, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31.
40) Stebbing J, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 Feb 27. pii: S1473-3099(20)30132-8.
 Appendix 1: Care Pathways for Mitigation of Drug-Induced Malignant Arrhythmias in COVID-19 Patients
Recommendations:
All COVID-19 patients should have the following:
When o de ing an EKG fo a COVID pa ien o moni o hei QTc elec he diagno i COVID o ale cardiology to expedite the formal reading
of the EKG.
Daily monitoring of electrolytes; maintain K > 4 and Mg > 2
All unnecessary QT prolonging drugs should be avoided or switched to alternatives whenever possible.
Recommendations:
A flowchart for the monitoring of potential malignant arrhythmias in these patients is shown below.
In all COVID-19 patients:
• Eliminate any unnecessary medication that may prolong the QT interval
• Keep K> 4.0 and Mg>2.0
Baseline ECG (at admission or within 30 days)
QTc < 470 ms, narrow QRS QTc > 470 ms, narrow QRS
or or
QTc < 500ms, wide QRS (>120 ms) QTc > 500 ms, wide QRS (>120 ms)
Telemetry not routinely required for QTc monitoring* Admit to telemetry No Telemetry Available
Check ECG 2 hrs after 2nd dose Check QTc on Discuss risk/benefit of therapy
telemetry 2 hrs after with Clinical Pharmacy, ID and
No Change in QTc QTc increase > 50 ms morning dose EP services
interval Or
absolute QTc > 500 ms QTc increase > 50 ms
Check daily ECG 2 hrs >Confirm QTc Verify by 12-lead ECG
after morning dose prolongation with EP
service >Confirm QTc
>Move to telemetry prolongation with EP
>Discuss with clinical service
pharmacy, ID and EP > Discuss with clinical
services pharmacy, ID and EP
services For extreme baseline QTc prolongation
QTc > 500 ms narrow QRS
* Telemetry may be considered for other clinical reason QTc > 550 wide QRS
Discuss risk/benefit of therapy with
EP and ID services
 Appendix 2: YNHH Acute Respiratory Failure with COVID- 19 MICU / SDU Triage Guidelines:
>4L NC with O2 sat
<93%
RR > 25 +/- AMS
RR < 25 +/- inability to
manage secretions
Obtain ABG
Obtain ABG and consult
MICU
pH>7.32 Hypercapnia with pH < 7.32
Consider SDU evaluation, Consult
reassess in 2-4 hours MICU
 Appendix 3: Enoxaparin Dosing Guidelines:
All COVID-19 patients should receive VTE prophylaxis with enoxaparin unless contraindicated. If D-dimer > 10 mg/L and critically ill, increase
to intermediate-dose weight-based VTE prophylaxis. If confirmed VTE, begin therapeutic enoxaparin unless contraindicated.
1) VTE prophylaxis in patients with D-dimer < 10 mg/L
CrCl 30 mL/min
o BMI < 40 kg/m2
Enoxaparin injection 40 mg sq daily
o BMI kg/m
Enoxaparin injection 40 mg sq Q12H
CrCl < 30 mL/min: Consult pharmacy and/or hematology for recommendations on enoxaparin dosing with anti-Xa level monitoring
2) If D-dimer 10 mg/L, increase to intermediate-dose weight-based VTE prophylaxis
Enoxaparin 0.5 mg/kg sq Q12H
CrCl < 30 mL/min: Consult pharmacy and/or hematology for enoxaparin with anti-Xa level monitoring
3) VTE Treatment- Confirmed VTE or high clinical suspicion for VTE
Enoxaparin 1 mg/kg sq Q12H
CrCl < 30 mL/min: Consult pharmacy and/or hematology for enoxaparin with anti-Xa level monitoring.